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This gene can be found on Chromosome 3 at location: 
49,371,585-49,424,530. 
Transcription 
The DNA sequence contains 5 exons and the transcript 




RhoA encodes a 21-kDa, 193 amino acids, small Rho 
GTPase; it displays potent oncogenic activity when 
overexpressed. 
RhoA structure:  
The N-terminal half of RhoA contains the majority of 
the amino acids involved in GTP binding and 
hydrolysis, together with the Switch 1 and 2 regions 
that change conformation between the GTP-bound and 
GDP-bound states. Several X-ray crystallographic 
structures of RhoA have been solved at high resolution. 
Amino acids essential for catalytic function are 
conserved in other Rho proteins, including Gly14, 
Thr19, Phe30, and Gln63, which are involved in 
binding, stabilization or regulation of GTP hydrolysis. 
RhoA protein is target for several bacterial toxins, 
which modify key conserved amino acids involved in 
their regulation. These include Clostridium botulinm 
exoenzyme C3 transferase, which modifies Asn41, and 
Toxin B, which acts on Thr37. 
The C-terminus of RhoA is essential for correct 
localization of the protein. RhoA is post-translationally 
modified by prenylation of a conserved C-terminal 
cysteine followed by methylation and proteolytic 
removal of the last three amino acids. The prenyl group 
(geranylgeranyl) anchors the GTPase into membranes 
and this modification is essential for its stability, cell 
growth, transformation, and cytoskeletal organization. 
Expression 
RhoA protein is expressed in all tissues tested. 
Localisation 
RhoA is found in the cytoplasm or at the plasma 
membrane. 
RhoA activity regulation: 
RhoA has intrinsic GTPase activity and shuttle between 
an inactive GDP-bound state and active GDP-bound 
state. In vitro, the exchange of GDP to GTP occurs 
very slowly, and is catalyzed by guanine nucleotide 
exchange factors (GEFs), which exchange GDP for 
GTP. GTPase activating proteins (GAPs) catalyze 
hydrolysis of the gamma phosphate of GTP. There are 
over 80 GEFs and 70 GAPs for Rho GTPases, whose 
activity is tightly regulated and can be highly specific. 
RhoA can be sequestered in the cytoplasm by guanine 
nucleotide dissociation inhibitors (RhoGDIs). These 
remove the Rho protein from the membrane by binding 
to the prenyl group and prevent its interaction with 
downstream effectors. 
RhoA effectors binding: 
To date, at least 11 proteins have been identified which 
directly interact with RhoA (ROCK1, ROCK2, PRK1/2 
PKN, Rhotekin, Rhophilin, kinectin, Citron Kinase, 
MBS, p76RBE, PKC epsilon and DB1 transcription 
factor). Some of these have been shown to contribute to 
specific responses downstream of RhoA.  
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Similarly to GEFs and GAPs, effectors bind to Rho 
both through the Switch 1 and 2 regions, but the amino 
acids involved in interaction with each target differ. 
Function 
RhoA regulates a diverse set of biological activities 
including actin organization, cell motility, cell polarity, 
gene transcription and cell-cycle progression. 
Role in actin organization:  
RhoA protein plays a central role in regulating cell 
shape, polarity and locomotion through their effects on 
actin polymerization, actomyosin contractility, cell 
adhesion, and microtubule dynamics. RhoA is believed 
to act primarily at the rear of migrating cells to promote 
detachment. 
RhoA directly stimulates actin polymerization through 
activiation of diaphanous-related formins (DRFs, also 
known as Dia proteins). These stimulate addition of 
actin monomers to the fast-growing end of actin 
filaments. DRFs act together with ROCKs to mediate 
Rho-induced stress fiber formation. ROCK-mediated 
phosphorylation of LIMK and consequent inhibition of 
cofilin also contributes to the increase in actin filaments 
in response to Rho. In addition, ROCKs induce 
actomyosin-based contractility and phosphorylate 
several proteins involved in regulating myosins and 
other actin-binding proteins. Actomyosin contractility 
is important in migrating cells for detachment of the 
rear. Microtubules are essential for determining cell
polarity as well as for vesicular locomotion and 
intracellular transport. The concerted action of ROCK 
and Dia is essential for the regulation of cell polarity 
and organization of microtubules. ROCK 
phosphorylates TAU and MAP2, proteins that regulate 
microtubule stability. 
RhoA plays a key role in regulating the integrity of 
cell-extracellular matrix and cell-cell adhesions, the 
latter including both adherens junctions and tight 
junctions. Loss of cell-cell junctions is required form 
the migration of epithelial cells and may be regulated 
reciprocally by ROCKs and DRFs. 
Role in cytokinesis:  
Cytokinesis requires actomyosin-based contraction. 
Inhibition of ROCK or citron kinase causes defects in 
cytokinesis resulting in multinucleate cells. 
Diaphanous-related formins (DRFs) are also implicated 
in this process, the DRF mDia1 localizes to the 
cleavage furrow during cytokinesis. DRFs could 
contribute to cytokinesis by stimulating local actin 
polymerization and/or by coordinating microtubules 
with actin filaments at the site of the contractile r ng. 
Role in cell cycle regulation:  
RhoA plays a pivotal role in G1 cell cycle progression, 
primarily through regulation of both cyclin D1 
expression, and the levels of the cyclin-dependent 
kinase inhibitors p21 and p27. Multiple pathways seem 
to link Rho proteins to the control of cyclin D1 levels. 
Many of these involve the activation of protein kinases, 
leading to the subsequent modulation of transcription 
factor activity. RhoA suppresses p21 levels in multiple 
normal and transformed cell lines. This effect appears 
to occur through a transcriptional mechanism but is 
independent of p53, a major transcriptional regulator of 
p21. RhoA plays an important role in determining the
levels of p27 through a pathway involving its effector, 
the Rho-associated kinases. 
Role in development:  
RhoA protein is required for processes involving cell
migration in development including: neurite outgrowth, 
dorsal closure, bone formation, and myogenesis. Rho-
loss of function is embryonically lethal in mouse 
development by E7. This is attributed to failure in 
gastrulation and an inability of cells to migrate. 
Role in transcriptional control:  
The relationship between many of the cellular functions 
mediated by RhoA with transcriptional regulation has 
been described. RhoA modulates the activity of SRF, 
NF-kappaB, c/EBPb, Stat3, Stat5, FHL-2, PAX6, 
GATA-4, E2F, Estrogen Receptor alpha, Estrogen 
Receptor beta, CREB, and transcription factors that
depend on the JNK and p38 MAP kinase pathways. 
Substrates to these kinases include c-Jun, ELK, PEA3, 
ATF2, MEF2A, Max and CHOP/2GADD153. 
Mutations 
Note: Several types of human cancers have been 
analyzed for RhoA mutations. Thus, breast, ovarian, 
renal, lung and colon specimens were surveyed for 
RhoA gene mutations and performed chromosomal 
analysis on 3p21. No mutations in RhoA were found, 
nor there a correlation between RhoA mRNA 





RhoA protein levels were significantly increased in 
breast cancer compared with the corresponding normal 
tissue. Of particular note, protein levels of RhoA were 
barely detectable in normal mammary tissue, but were 
highly expressed in all breast tumors tested. 
Interestingly, RhoA protein levels correlated with 
increasing breast tumor grade. 
Ovarian carcinoma 
Oncogenesis 
RhoA mRNA is higher in ovarian carcinoma, 
especially of serous histological type, than in benign 
tumors. The expression of the protein is further 
upregulated in tumors of stages III/IV when compared 
to those of stages I/II. Analysis of matched pairs of 
primary and metastatic lesions showed that expression 
of both RhoA mRNA was significantly higher in 
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metastatic lesions of peritoneal dissemination than in 
the respective primary tumors. 
Testicular cancer 
Oncogenesis 
Protein expression of RhoA and its two major 
downstream effectors ROCK-I and ROCK-II, was 
significantly higher in tumor tissue than in nontumor 
tissue from 57 patients with testicular germ cell tumors. 
The expression was greater in tumors of higher stage  
than lower stages, thus RhoA correlates with tumor 
stage and aggressiveness. 
Pelvic/ureteric cancer 
Oncogenesis 
Both mRNA and protein level of RhoA are elevated in 
pelvic/ureteric cancer with an increase in lymph node 
metastasis. The expression levels of RhoA were related 
to poorly differentiated grade and muscle invasion and 
associated with a shorter disease-free and overall 
survival. These findings suggest that RhoA is involved 
in the invasion and metastasis of upper urinary tract 
cancer, indicating that RhoA may be a useful 
prognostic factor in this disease. 
Bladder cancer 
Oncogenesis 
A similar deregulation of RhoA is observed in bladder 
cancer. In this sense, RhoA and ROCK protein levels 
are elevated in tumors, again with higher expression in 
less differentiated tumors and metastatic lymph nodes 
compared to normal bladder. Interestingly, the levels of 
expression of RhoA and ROCK correlated positively 
with one another suggesting that the GTPase and its 
effector synergize to promote tumor progression. 
Lung tumors 
Oncogenesis 
Of the two major forms of lung cancer, small cell lung 
carcinoma (SCLC) and non-small cell lung carcinoma 
(NSCLC), the former has a greater metastatic potential. 
The expression and activation of RhoA is greater in 
SCLC than NSCLC cell lines. It has been observed that 
RhoA repress the expression of nitric oxide synthase-2 
(NOS-2) in a lung cancer-derived cell line. Since NOS-
2 activity is related to reduced proliferation, RhoA 
could be eliminating this antiproliferative signal in lung 
carcinogenesis. In addition, inhibition of RhoA by C3 
exoenzyme or through ADP-ribosylation leads to an 
increase in cadherin-based adhesion and loss of 
motility of SCLC. 
Oesophageal squamous cell carcinoma 
Oncogenesis 
There were significant correlations among RhoA 
overexpression and TNM clinical classification, 
lymphatic invasion, and blood-vessel invasion. The 
five-year survival rates for ESCC patients with RhoA 
overexpression were significantly lower than those in 
patients with RhoA under-expression. The expression 
of RhoA protein appeared to be correlated with tumor 
progression of ESCC. Patients with RhoA 
overexpression tended to have poor prognosis 
compared with patients with RhoA under-expression. 
Gastric cancer 
Oncogenesis 
RhoA was found frequently overexpressed in gastric 
cancer tissues compared with normal tissues, 
suggesting that RhoA may play a critical role in the 
carcinogenesis of this type of cancer. The interfernce 
of RhoA expression and/or activity could significantly 
inhibit the proliferation and tumorigenicity of gastric 
cancer cells and enhance the chemosensitivity to 




Invasiveness of hepatocellular carcinoma is facilitted 
by the Rho/Rho-kinase pathway and likely to be 
relevant to tumor progression. The Rho/Rho-kinase 
may be useful as a prognostic indicator and in the 
development of novel therapeutic strategies. 
Pancreatic tumor 
Oncogenesis 
Although overexpression of RhoA has not been 
detected in any pancreatic tumor tissue to date, it might 
nevertheless also be involved in pancreatic tumors. 
Two 3-hydroxy 3methylgultaryl coenzyme A (HMG- 
CoA) reductase inhibitors, fluvastatin and lovastatin 
inhibit human pancreatic cancer ell invasion and 
metastasis in a Rho-dependent manner. These 
inhibitors prevent the synthesis of cholesterol 
precursors necessary for proper membrane 
translocation of Rho protein. 
Colorectal cancer 
Oncogenesis 
A high proportion of colon cancers overexpress RhoA 
and several aspects of colon tumor biology have been 
related to Rho GTPases. Leptin receptor and leptin-
induced migration of colonic epithelial cancer cells is 
dependent on RhoA, since inhibition of the activity of 
the GTPase through introduction of dominant negative 
mutants completely abolishes the invasive capacity of 
the tumor cells. 
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